Status:
COMPLETED
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line ...
Eligibility Criteria
Inclusion
- Female patients, \>/= 18 years of age
- HER2-positive metastatic breast cancer or locally advanced breast cancer
- Systemic treatment included Herceptin as 1st line therapy
- Without progression for at least 3 years after the beginning of Herceptin treatment
- Alive or not alive and treated or not treated with Herceptin at the time of inclusion
Exclusion
- Disease progression \<3 years after beginning 1st-line therapy with Herceptin
Key Trial Info
Start Date :
March 28 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 16 2012
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT01480674
Start Date
March 28 2011
End Date
November 16 2012
Last Update
August 16 2017
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Du Docteur Calabet; Cromg
Agen, France, 47000
2
C.H. Du Pays D'aix En Provence Service du Dr Blanc
Aix-en-Provence, France, 13616
3
Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire
Aix-en-Provence, France, 13617
4
Chd Castelluccio; Oncologie
Ajaccio, France, 20176